NTGN stock forecast
Our latest prediction for BioNTech US, Inc.'s stock price was made on the March 24, 2020 when the stock price was at 2.23$.
In the short term (2weeks), NTGN's stock price should outperform the market by 3.44%. During that period the price should oscillate between -13.87% and +22.33%.
In the medium term (3months), NTGN's stock price should outperform the market by 10.12%. During that period the price should oscillate between -39.40% and +56.10%.Get email alerts
Create a solid portfolio with NTGN
About BioNTech US, Inc.
BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.86$ per share.
The book value per share is 4.92$
Three months stock forecastMarch 24, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|